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Objective: Tissue-engineered blood vessels (TEBV) have been proposed as an alternative to prosthetic grafts for dialysis
access. However, arteriovenous (AV) grafts must withstand extreme flow rates and frequent needle trauma. In a
proof-of-concept study, we sought to determine whether scaffold-based TEBV could withstand the hemodynamic and
mechanical challenges of chronic dialysis access.
Methods: TEBV were constructed using decellularized arterial scaffolds seeded with autologous ovine endothelial cells
(EC) derived from circulating endothelial progenitor cells (EPC) using a novel high-affinity capture approach. Seeded
scaffolds were preconditioned to arterial pressure and flow in a bioreactor for 2 weeks prior to implantation to create
carotid artery to jugular vein AV grafts in each animal. TEBV were healed for 1 month before initiating percutaneous
needle puncture 3 days/week. TEBV wall geometry and patency were monitored using duplex imaging and were either
explanted for histologic analysis at 2 months (n  5) or followed for up to 6 months until venous outflow stenosis
threatened AV graft patency (n  6).
Results: Despite high flow, TEBV maintained stable geometry with only modest wall dilation (under 6%) by 4 months
after implantation. Needle access was well tolerated with a single puncture site complication, a small pseudoaneurysm,
occurring in the late group. Time-to-hemostasis at puncture sites averaged 4 2minutes. Histologic analysis at 2 months
demonstrated repopulation of the outer TEBVwall by host cells and healing of needle punctures by cellular ingrowth and
new matrix deposition along the tract. TEBV followed beyond 2 months showed stable wall geometry but, consistent with
the primary mode of clinical AV graft failure, all TEBV eventually developed venous anastomotic stenosis (mean, 4.4  0.9
months; range, 3.3-5.6 months postimplantation; n  6).
Conclusions: This pilot study supports the concept of creating dialysis access from scaffold-based autologous TEBV.
Engineered AV grafts were created within a clinically relevant time frame and demonstrated stable wall geometry despite
high flow and repeated puncture. Cellular ingrowth and puncture site healing may improve wall durability, but venous
outflow stenosis remains the primary mode of TEBV graft failure in the ovine model. ( J Vasc Surg 2012;56:783-93.)
Clinical Relevance: While the ideal dialysis access is created with a patient’s own vein, this is often not available in a
significant portion of patients. Catheter-based dialysis presents increased risks to the patient, and prosthetic arterio-
venous grafts are at risk for infection, mechanical failure, and graft failure. This study examines the role of bioengineered
vessels as an alternative option for dialysis access in an ovine model of vascular access. Bioreactor-conditioned,
decellularized scaffolds lined with endothelial cells are examined for parameters such as hemostasis, structural integrity,
needlestick healing, and graft patency.
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tMore than 500,000 people in the United States have
end-stage kidney disease requiring dialysis for survival,1,2
and the vast majority rely on hemodialysis requiring regular
access to the circulation. Vascular access via an autogenous
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doi:10.1016/j.jvs.2012.02.030rteriovenous (AV) hemodialysis access is preferred, but
nfortunately, many patients lack suitable arm veins for this
rocedure and instead rely on chronic central venous cath-
ters or prosthetic AV grafts. Overall, the longevity of both
utogenous and prosthetic AV hemodialysis access are dis-
al, with50% patency at only 2 years.3 Ultimately, these
ailures lead to repeated hospitalization and ultimately im-
act long-term survival among hemodialysis patients.
In patients with inadequate vein, a prosthetic hemodi-
lysis AV access is preferred over a central venous catheter,
ut current prosthetic grafts perform poorly in the long
erm because of high rates of thrombosis and venous out-
ow stenosis resulting from neointimal hyperplasia.4-6
rosthetic hemodialysis grafts are also more susceptible to
nfection and graft wall pseudoaneurysms from repeated
eedle puncture deteriorating the fabric wall. These limita-
ions may reflect mismatch in compliance between stiff
rosthetic grafts and compliant native vessels, the absence
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September 2012784 Tillman et alof an antithrombogenic endothelial lining, persistence of
prosthetic material predisposed to infection for the life of
the graft, and lack of graft wall cellularity to facilitate
healing of needle trauma.
Tissue engineering has been proposed as one approach
to address the limitations of AV grafts for patients lacking
superficial veins. Initial clinical studies of tissue-engineered
blood vessels (TEBV) for use in creating AV grafts em-
ployed vessels constructed from sheets of cultured skin
fibroblasts and seeded with endothelial cells (ECs).7 While
these were exciting examples of the potential to engineer
vascular access, prolonged periods of cell culture prior to
implantation (6-9 months) and issues with vessel wall du-
rability have tempered enthusiasm.8,9 Designing an autol-
ogous TEBV for AV access that requires only a brief period
of vessel construction and that demonstrates durable wall
structure after repeated access would significantly advance
the field.
We have previously demonstrated that TEBV created
by seeding host cells onto a decellularized vascular scaffold
function successfully for arterial reconstruction in sheep,
with stable wall geometry at more than 4 months after
implantation.10 In the present study, we investigated the
feasibility of adapting this approach for engineering AV
access. Previous studies have demonstrated a favorable
compliance profile of TEBV constructed from decellular-
ized porcine vessels.11,12 We hypothesized that decellular-
ized scaffolds seeded with host ECs and preconditioned by
shear stress and pulsatile flow would better resist acute
thrombosis, remodel to incorporate host cells into the
vessel wall, and maintain stable wall geometry in the face of
high blood flow and repeated needle puncture.
METHODS
Culture of autologous progenitor-derived ECs. All
animal procedures were approved by the Wake Forest Uni-
versity Institutional Animal Care and Use Committee and
complied with the Guide for Care and Use of Laboratory
Animals by the Institute of Laboratory Animal Resources,
Commission on Life Sciences, National Research Council.
Female Dorper Cross sheep were purchased at 4 to 12
months of age andmaintained on standard chow (Rumilab,
PMI, St. Louis, MO). EC for use in seeding TEBV were
derived from autologous endothelial progenitor cells
(EPC) initially isolated from peripheral blood using a
CD133 antibody capture system.13 Briefly, an extracorpo-
real circuit was created using catheters inserted into the
femoral artery and vein, and these were connected to either
end of a flow-through cassette containing beads conjugated
to anti-CD133 antibody. Approximately 1800 mL blood
was circulated through the circuit to capture CD133
EPCs. All blood was returned to the animal by flushing the
circuit with saline, and the catheters were then removed.
Captured cells were released from the cassette with trypsin
and plated on plastic dishes in endothelial growth media
(EGM-2; Cambrex, East Rutherford, NJ). EC colonies
emerged by 10 days and were expanded for three to four
passages prior to TEBV seeding. Cells were characterized uhenotypically by observing “cobblestone” growth on
lastic culture dishes, by their expression of vWF,
EGFR2, and endothelial NOS, and through binding of
lex lectin, as previously described.13 The time from EPC
arvest to graft seeding averaged between 2 and 3 weeks.
TEBV scaffold preparation, seeding, and pre-
onditioning. Decellularized porcine carotid artery seg-
ents were prepared as previously described14 and then
ashed, frozen, lyophilized, and sterilized with ethylene
xide. Immediately prior to EC seeding, scaffolds were
ehydrated with sterile phosphate-buffered saline and
ounted in a sterile bioreactor to create a closed circuit
nto the lumen. Scaffolds were then gently distended by
nfusing ECs into the lumen at a density of 2  106
ells/mL in EGM-2 and rotated slowly for 2 hours at 37°C
o facilitate uniform lumen seeding. Media was then circu-
ated through the graft lumen using a gear pump (Ismatec,
lattbrugg, Switzerland) controlled by custom software
LabVIEW; National Instruments Corporation, Austin,
ex). Nonpulsatile flowwas increased in a step-wise fashion
ntil normal arterial shear stress was achieved on day 5, and
hen the flow was transitioned to pulsatile flow (60 cycles/
in) with shear stress of 9.9 dyne/cm2 in diastole and 13.2
yne/cm2 in systole. This was maintained until implanta-
ion on day 14, as previously described.15
AV graft model. We adapted the ovine AV dialysis
ccess model characterized by Kohler and Kirkman for
tudies of polytetrafluoroethylene (PTFE) graft failure.16
ne day prior to surgery, animals received clopidogrel (75
g) and aspirin (325mg). The day of surgery, animals were
edated with ketamine (30 mg/kg intramuscularly), intu-
ated, and placed under general anesthesia. The common
arotid artery and external jugular vein were exposed, hep-
rin was administered (100 U/kg intravenously), and a
reconditioned TEBV was inserted as a loop graft (5-mm
iameter, 6-cm length) between the artery and vein using
eveled end-to-side anastomoses with running 6-0 poly-
ropylene sutures. Antiplatelet agents were continued daily
or 1 week after surgery.
Animals were divided into two groups: In the early
roup (n  7), TEBV were healed for 1 month and then
unctured three times per week for a 2nd month prior to
eing explanted for histologic analysis. In the late group
n  8), TEBV were healed for 1 month and then punc-
ured three times per week for up to 6 months, with earlier
etrieval if venous outflow stenosis threatened graft pa-
ency. Grafts were regularly screened for outflow stenosis
y palpation for reduced or absent thrill and by duplex
ltrasound of the distal anastomosis (see below).
Needle access. After an initial month of healing, all
EBV were punctured three times per week in the midgraft
ith a 16-gauge needle to simulate clinical access for he-
odialysis. Aspiration of 5-mL arterial blood was used to
onfirm needle entry into the TEBV lumen. Blood was
hen returned, the needle removed, and digital pressure
pplied until hemostasis was obtained. Time to achieve
uncture site hemostasis was measured to the nearest min-
te beginning at 2 minutes and recorded. Pressure was
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Volume 56, Number 3 Tillman et al 785continued for at least 5 minutes if hemostasis was docu-
mented at an earlier time point.
TEBV patency and geometry. TEBV were moni-
tored for patency, changes in wall diameter, and for anas-
tomotic stenosis by palpation, duplex ultrasound, and an-
giography. Implanted TEBV were examined by palpation
three times per week and by duplex ultrasound monthly
(Acuson Sequoia, Mountain View, Calif). Flow velocities
and B-mode imaging were used to exclude significant
stenosis, dilation, or other complicating features. Midgraft
cross-sectional diameters were recorded inmmover time to
document flow-induced dilation. In the late group, grafts
suspected of developing outflow stenosis also underwent
digital subtraction angiography or computed tomography
angiography to confirm a lesion prior to explanting TEBV.
TEBV histology. TEBV were removed en bloc at
necropsy with the carotid artery and jugular vein, rinsed
free of blood with saline, and then fixed by perfusion with
10% formalin. Midgraft rings were then embedded in par-
affin and sections cut for histology. Sequential sections
from each block were stained with hematoxylin and eosin,
picrosirius red (PSR), and Verhoeff van Giesen (VVG)
stains. Slides stained with PSR were viewed under polarized
light to define collagen fibrils in sections, as previously
described.17 Immunohistochemistry was performed on ad-
jacent sections using antibodies specific for the smooth
muscle cell markers, alpha-actin and SM22-alpha as previ-
ously described.18 Labeling was detected with the Vectastain
Elite ABC kit (VectorLabs, Burlingame, Calif) using 3,3’-
diaminobenzidine as the chromogen (Sigma, St. Louis, Mo).
Sections were viewed with standard light microscopy except
for PSR-stained sections, which were viewed with polarized
light.
Cellular density was determined by counting nuclei per
high-power field in three nonoverlapping fields across the
TEBV wall from the external elastic lamina to the internal
elastic lamina, repeated in each of four quadrants around
the vessel wall by a predefined algorithm. Nuclear density
was then averaged in each quadrant and reported as mean
of means  SEM for each graft ring. The same counting
algorithm was then applied to adjacent sections of each
TEBVmidgraft ring to determine the numbers of cells that
stained for the smooth muscle cell markers alpha-actin and
SM22-alpha.
VVG sections were examined for needle puncture pen-
etration of the vessel wall, identified by radial disruption of
the elastic layers within the TEBV wall and associated
thrombus or neointimal-like scar tissue within the needle
tract. Adjacent sections were then stained with hematoxylin
and eosin, PSR, and SM22-alpha. Cell density within the
TEBV wall at sites of needle puncture was also quantified,
counting nuclei per high-power field in four quadrants and
compared to adjacent uninjured TEBV wall.
Statistical analysis. Descriptive statistics are reported
as mean  standard deviation for continuous data and
number (percent) for categorical data. Group-wise com-
parisons of mean cellular counts based on needle puncture
status were made using nonparametric methods (Wilcoxon wank-sum test, Kruskal-Wallis test). Results were evaluated
or significance using   0.05. All statistical analyses were
erformed using SAS 9.1 software (SAS Institute, Cary,
C).
ESULTS
EC isolation and seeding. EC derived from CD133-
ositive progenitors were grown from each animal and used
o seed the lumen surface of decellularized artery scaffolds
o construct autologous TEBVs (Fig 1). After plating EPCs
rom affinity cassettes, adherent cells were expanded and
assaged to derive ECs. Adequate numbers of EC for use in
eeding TEBV were available by 3 weeks after initiating
ultures and were at least passage two and no more than
assage five at the time of seeding. ECs demonstrated
ypical cobblestone morphology under phase-contrast mi-
roscopy when allowed to grow to a confluent monolayer.
he resulting EC phenotype included expression of eNOS,
WF, VEGFR2, and binding of ulex-lectin as shown in our
revious publication detailing the CD133-affinity capture
assette.13 Upon completion of preconditioning to pulsa-
ile flow, TEBVs were lined with a confluent monolayer of
ndothelium along the lumen surface (Fig 1, B). The
eriod from cell harvest to TEBV implantation was be-
ween 4 and 5 weeks.
Surgical handling of TEBV. Each animal received an
utologous TEBV with an average wall diameter of 5 mm,
mplanted in a loop configuration between the carotid
rtery and internal jugular vein as a subcutaneous AV graft
Fig 1, C). Hemostasis at the suture line occurred rapidly
ithout the need for topical hemostatics or reversal of sys-
emic heparin, despite preoperative administration of clopi-
ogrel and aspirin. No significant transudation of blood oc-
urred through the TEBV wall when grafts were pressurized.
ll TEBV were visible through the skin following closure of
he surgical incision with a prominent palpable thrill. This
uperficial location recapitulated that of a subcutaneous pros-
hetic loop graft used clinically (Fig 1, D) and facilitated
eedle access starting 1 month after implantation.
Early and late patency of TEBV AV grafts. Seven
EBV were implanted into animals assigned to the
-month group and eight into animals assigned to the late
roup. Two grafts in each group occluded acutely prior to
he first duplex examination so that 11 TEBV were patent
fter the initial month of healing (73%; Table 1). The
tiology of early graft thrombosis was thought to be related
o kinking at the graft apex from too small a subcutaneous
ocket in two cases, while no cause was identified for the
ther two failures. All remaining grafts (n  11) began
egular needle access at week 5 and completed the 2nd
onth of healing uneventfully. In the late group, grafts
emained patent despite continued needle access for
n average of 4.4  0.9 months (range, 3.3-5.6 months;
 6).
Consistent with the most common mode of AV graft
ailure in clinical studies, and with previous studies of PTFE
raft failure in the ovine model,16 all late TEBV failures
ere the result of outflow stenosis from intimal hyperplasia
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September 2012786 Tillman et alat the venous anastomosis (Fig 2). Two of six grafts in the
late group occluded before they could be removed for
analysis at 3.3 and 3.5 months. Both demonstrated critical
stenoses at the distal suture line. The remaining four grafts
in the late group were imaged with arteriography after
identifying outflow stenosis by loss of a palpable thrill
and/or by duplex imaging and were then explanted while
still patent at 4.3, 4.7, 5.4, and 5.6 months. Each demon-
strated typical fibrous neointimal lesions at the TEBV–vein
anastomosis but were free of stenosis along their length as
documented by angiography, gross inspection, and histology.
TEBV wall integrity in response to AV flow and
repeated puncture. TEBV grafts initially demonstrated
continuous high-velocity diastolic flow characteristic of an
AV graft (Fig 3, B). Monthly color flow duplex imaging
demonstrated stable wall architecture with only modest
dilation of the TEBV wall at late time points, but there was
6% increase in mean diameter out to 4 months (Fig 3, E;
P  NS at all time points) despite high flow and repeated
needle puncture. Only one TEBV showedmore than a 20%
Fig 1. Preimplant specimens and operative images. Ima
endothelial cell (EC)-lined scaffold stained with the nucle
present on the scaffold lumen at the time of implant (B).
in a loop configuration between carotid artery (CA) and
(SCM). Side view image of mature arteriovenous (AV
subcutaneous graft and dilated proximal vein (D).
Table I. Experimental groups of implanted tissue-enginee
Healing phase
(0-1 month)
Needlest
(1 m
Early group (2 months) n  7 n 
Late group (6 months) n  8 n 
Vascular grafts seeded with endothelial cells were assigned to early (2 mon
healing phase of 1 month from each group underwent large-bore needle acce
occlusions are shown during needle access phase (grafts 1 month). Averagincrease in wall diameter, and none demonstrated stricture (r stenosis within the AV graft body away from an anasto-
osis. In contrast, outflow vein diameter increased sub-
tantially as is typical of vein adaptation to AV flow (Fig 2),
nd this was exaggerated by poststenotic flow near the
enous anastomosis (Fig 2, B andC). No AV grafts in either
roup developed infection, suture line disruption, or wall
neurysm. One graft in the late group was found to have a
mall pseudoaneurysm fromneedle access on duplex imaging.
TEBV wall histology. EC retention on the TEBV
urface was documented after bioreactor preconditioning
o flow in vitro (Fig I, B). Histologic staining for ECs in
ross-sections of TEBV removed at 2 months demon-
trated an intact EC monolayer in 40% of midgraft rings
hile in the late group, 50% of midgraft rings showed EC
overage (P  NS; Fig 4).
At necropsy, gross examination of AV grafts in the late
roup showed venous anastomotic stenosis in all speci-
ens. To confirm the etiology of the anastomotic lesions,
istologic staining with hematoxylin and eosin and VVG
lyophilized decellularized scaffold (A) and a preimplant
in DAPI, which demonstrates an endothelial monolayer
ative photograph of bioengineered graft (C) placement
lar vein (JV) overlying the sternocleidomastoid muscle
ft at 2 months postimplantation depicting the visible
lood vessel (TEBV) arteriovenous grafts
ase Dates of occlusion
(1 month)
Average patency
(1 month)
No occlusions 2 months
3.3, 3.5, 4.3, 4.7, 5.4, 5.6
months
4.4  0.9 months
d late (6 month) groups. Following implantation, animals completing a
ee times per week until either 2- (early) or 6-month (late) time points. Graft
ncy in months for all grafts during the needlestick phase are also shown.ges of
ar sta
Oper
jugu
) grared b
ick ph
onth)
5
6
th) anelastin) was performed. Cells surrounded by proteoglycan-
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Volume 56, Number 3 Tillman et al 787Fig 2. Angiographic evaluation of tissue-engineered blood vessel (TEBV) grafts. Representative anterior-to-posterior
views of grafts using computed tomography angiography (A and B) illustrate stable TEBV wall geometry at 2 and 6
months. However, a typical stenosis is evident at the distal anastomosis of the late graft on computed tomography
angiography (B) and digital subtraction fluoroscopy (C). The digital subtraction fluoroscopy image also shows a jet of
contrast through the stenosis with adjacent vein wall dilation (C). Arrows mark the distal anastomosis of each graft.Fig 3. Flow patterns and graft geometry of engineered vessels. Compared with traditional triphasic flow of the
common carotid artery (A), tissue-engineered blood vessel (TEBV) grafts exhibit traditional turbulent flow pattern by
pulsed-wave Doppler of the arteriovenous (AV) midgraft (B) as well as by color flow of the loop-configured graft (C).
Graft geometry (D) was assessed by ultrasound measurements monthly illustrating only minimal increase in diameter,
averaging6% increase over the 6-month study (E). *At 150 days, one data point was missing despite patency of two
grafts.
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September 2012788 Tillman et alrich extracellular matrix typical of neointimal hyperplasia
was confirmed at venous anastomoses (Fig 5), while mid-
graft rings were free of significant neointima.
To assess host response and cell infiltration into the
TEBV wall, midgraft sections were examined histologically
for density of cells in the medial layer of the TEBV scaffold.
By 2 months, a significant number of cells had invaded the
scaffold medial layer, more so in the outer media, suggest-
ing that the scaffold was repopulated from the outside
rather than from the lumen (Fig 6). Cell density per
mm2 in midgraft rings was not significantly different for
the 2-month group and the 6-month group (P  .05;
Table II).
Histologic examination of needlestick sites.
Beginning at 1 month postimplantation, AV grafts under-
went needle puncture three times per week. Hemostasis
time averaged 4  2 minutes of compression. During the
needle stick phase, graft geometry remained stable with a
single small pseudoaneurysm occurring as noted above.
Upon explantation, acute puncture sites were easily identi-
fied by tangential disruption of the elastic lamellae and by
the presence of thrombus and/or intact red cells identified
in the needle tract. Occasionally, a small mural thrombus
was also seen adherent to the luminal surface of an acute
puncture site. Healed puncture sites were characterized by
replacement of thrombus with -actin positive cells
and new extracellular matrix. Relatively acute punctures
showed little collagen fiber formation on PSR staining,
while older puncture sites showed significant new collagen
staining, suggesting a repair process analogous to wound
Fig 4. Histologic evaluation of endothelial monolayer
(400X) revealed an intact endothelial monolayer on sever
specimens. At 2 months, scanning electron microscopy (
midgraft section. Scale bar shown is 50 M.healing (Fig 7). There were no statistically significant dif- perences in puncture site cellularity compared with cellular-
ty of the adjacent TEBV sections without punctures, in-
luding density of cells expressing smooth muscle markers
-actin and SM22-alpha (P  .05).
ISCUSSION
Vascular access remains a major medical and economic
urdle for the growing population of patients with end-
tage kidney disease.4 In instances where autologous vas-
ular grafts are unavailable, indwelling dialysis catheters are
ssociated with increased morbidity and mortality. Pros-
hetic AV grafts have served as an alternative, but frequent
omplications have encouraged a search for a vascular sub-
titute that performs in a manner similar to an autologous
essel.4,5 Recent advances in regenerative medicine have
ulminated in the successful creation of a blood vessel lined
ith EC that has shown promise in arterial replacement and
V grafts.7,10,14,19,20 The design criteria for access grafts
or dialysis are very demanding because of the need to
olerate repeated needle trauma and high-flow conditions,
nd the present study sought to determine whether bioen-
ineered blood vessels using cell-seeded vascular scaffolds
ould be used for this purpose. Previous ex vivo studies15
ave highlighted the importance of bioreactor precondi-
ioning, including improved EC coverage and resistance to
dherence of platelets. In this study, we demonstrate that
EBV composed of EPC-derived EC seeded on decellular-
zed vascular scaffolds can be used effectively as AV hemo-
ialysis grafts and are able to maintain their structural
ntegrity even when exposed to dozens of repeated needle
xplanted specimens. Hematoxylin and eosin histology
onth (A) and projected 6-month (B) explant midgraft
) (C) reveals endothelial confluency on a representativeon e
al 2-m
500Xunctures.
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Volume 56, Number 3 Tillman et al 789From a clinical perspective, patency is a central goal in
AV graft implantation. Factors that contribute to failure of
implanted vascular grafts include thrombosis, intimal hy-
perplasia, and infection.4,5,16 The critical role of EC in
preventing thrombosis has been well documented in the
literature.21-23 Not surprisingly, EC have been described in
several other arterial replacement models10,19,20 for the
prevention of thrombosis. EC can be obtained from a
number of sources in the body, but the identification of
peripheral circulating EPC has allowed for minimally inva-
sive access to progenitors that can be used to obtain large
numbers of autologous EC.13,24-27 Of note, EPC numbers
may be reduced in populations with vascular disease and
renal failure,28,29 and it is unclear whether or not our
approach will be more challenging in these populations. A
number of investigators have shown that EC can be at-
tached to the luminal surface of vascular graft con-
duits10,14,19,20 for the purposes of arterial replacement. To
ensure that the EC placed onto a scaffold maintain a
durable monolayer on the luminal surface under these
conditions, we and others have used a bioreactor system to
precondition endothelialized grafts.15,30-33 Our bioreactor
system was designed to gradually introduce physiological
hemodynamic conditions of a native artery by controlling
pressure and flow through a computerized algorithm. De-
fects in the endothelium have been shown to increase the
Fig 5. Evaluation of intimal hyperplasia at distal graft an
observed between the internal elastic lamina and the lum
with Verhoeff van Giesen (VVG), sections from the distal
images are shown at 100 magnification with a scale barrisk of thrombosis,34,35 and it is now believed that this type of preconditioning is a critical component of the endothe-
ial coating process and ensures confluent coverage of the
raft lumen. Our group has reported the importance of
hear stress and pulsatile conditioning to the expression of
ndothelial functional markers and resistance to platelet
dherence.15 Beyond previous studies of seeding EC on
rosthetic grafts, our approach incorporated more exten-
ive bioengineering with a complex scaffold decellulariza-
ion process, EPC capture system, EPC-to-EC differentia-
ion, cell seeding, and preconditioning to pulsatile flow in a
ioreactor, all within approximately 5 weeks. Distinct from
urrent clinically available decellularized grafts, which are
reated with aldehyde fixation and thus remain largely
cellular after implantation, the scaffolds used in this study
ere not aldehyde fixed to facilitate cellular ingrowth,
hich will be necessary for a stable vessel wall architecture
nd healing needle trauma over time.
In contrast to the regularity of arterial flow, AV flow is
haracterized by supraphysiological flow rates causing tur-
ulence, which increases the mechanical forces exerted on
he endothelium. Our previous findings in an arterial inter-
osition model showed the importance of endothelium in
aintaining TEBV patency.10 In the present study, we
reconditioned the seeded EC to arterial flow and pres-
ures, as our bioreactors were not capable of applying shear
ates as extreme as in AV grafts. However, we have previ-
oses. Compared with the absence of intimal thickening
both native artery (A) and midgraft section (B) stained
us anastomosis reveal marked intimal thickening (C). All
00 M.astom
en in
venously demonstrated that this protocol supports EC reten-
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September 2012790 Tillman et altion in TEBV inserted into an ex vivo AV graft circuit.15
While explanted vessels were not processed for en face
analysis with scanning electron microscopy to quantify the
extent of lumen surface coverage, cross-sectional histology,
which can underestimate the extent of EC coverage,
Fig 6. Histologic evaluation of explant midgraft sectio
native artery (A) stained with hematoxylin and eosin, a r
monolayer on the luminal side of the internal elastic lam
by 6 months (C). Verhoeff van Giesen (VVG) staining re
(E), and 6-month explant (F). The scale bar is 200 M.
Table II. Comparison of cellularity among explanted
tissue-engineered blood vessel (TEBV) arteriovenous
grafts
Staining condition
2 months
cells/mm3
6 months
cells/mm3
All cells (inner media) 1840 2262
All cells (center media) 2869 3205
All cells (outer media) 4880 4948
All cells (mean) 3196 3471
Actin (inner media) 794 900
Actin (center media) 1497 1438
Actin (outer media) 2069 1429
SM22 (inner media) 183 352
SM22 (center media) 371 371
SM22 (outer media) 269 248
Shown are total cellularity, actin-positive cells, and SM22-positive cells at the
inner, center, and outer media layers for 2 months (n  5) and 6 months
(n  6). No significant difference was observed among the mean of all cells
between 2 and 6 months (P  .05).showed complete EC coverage in nearly half of the midves- rel sections. Maintenance of graft integrity is critical when
esigning conduits for clinical applications and is of para-
ount importance in the design of a vessel that must
olerate repeated needle puncture, as in the case of an AV
raft to be used for vascular access. In this study, we have
sed decellularized tissue scaffolds derived from porcine
rteries. These were processed to remove all cells, leaving
nly the extracellular matrix scaffold that has a stress and
urst profile comparable to native vessels.14 The approach
as been previously used successfully for arterial grafts10
ut to 4 months with stable structure consistent with the
table TEBV wall geometry observed in the present study.
he lack of dilation over time, while reassuring from the
erspective of TEBV wall integrity, was actually surprising.
e expected some wall dilation to occur at later time points
n response to high flow once the scaffold had been repop-
lated with host smooth muscle cells. The lack of dilation
ay reflect incomplete repopulation of the TEBV media,
articularly in the inner wall where communication be-
ween EC and medial cells would be critical in relaying
iochemical cues from high shear at the endothelium.
Unlike arterial grafts, TEBV used as AV grafts must
how durability when subjected to repeated puncture with
large-bore needle. Associated clinical characteristics in-
lude cellular healing of stick sites, a lack of pseudoaneu-
illustrated at a magnification of 100X, compared with
ntative preimplant graft (B) reveals only an endothelial
rrow) compared with increased medial cellularity noted
intact elastin layers in native artery (D), preimplant graftns. As
eprese
ina (a
vealsysm formation, and timely hemostasis after needle re-
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Volume 56, Number 3 Tillman et al 791moval. The average hemostasis time was under 5 minutes
with external compression, comparable to venous or pros-
thetic AV grafts used clinically. Further, despite repeated
access with a large-bore needle, there were no episodes of
graft occlusion during the actual needle access phase and
only one small pseudoaneurysm occurred in a late graft that
remained patent until explantation. Several histologic find-
ings at puncture sites support TEBV repair through a
process similar in appearance to neointima formation. Early
punctures showed ingrowth of actin-positive smooth mus-
cle and proteoglycan-rich matrix with little organized col-
lagen. In chronic puncture sites, more PSR staining sug-
gested remodeling of the healed puncture with collagen
deposition. This progression would be analogous to wound
maturation in other tissues.
Another key feature of engineered grafts observed in
this study was the population of the scaffold with host cells.
This finding of ingrowth of host cells is consistent with
prior studies involving engineered vessels and other tis-
sues.10,36 Our approach to TEBV for vascular access as-
sumes that scaffolds become repopulated by host cells, as
seen in our previous study of arterial grafting in the ovine
model and that this cellularity then enhances wall healing of
needle trauma. Moreover, a fully populated media likely
reduces the risk of infection compared with the chronic
foreign body risk associated with permanent prosthetic
Fig 7. Needlestick histology at 100 magnification re
needlestick sites (A-C) were differentiated from healed
(arrow). Compared with hematoxylin and eosin stain of
degrees of cellularity at needlesticks (A andD), but a void
collagen deposition in the healed needlestick (F). B an
sections used to identify needlestick sites as disruption ograft wall. Histologic analysis in the present study showed a sarked difference in the appearance of cells and surround-
ng matrix in the injured and uninjured wall (resembling
eointima within the needle tract), but cell density was
imilar in injured and uninjured media, including the frac-
ion of cells expressing smooth muscle cell markers.
The primary mode of failure in the late group was
enous anastomotic stenosis from neointimal hyperplasia.
his is consistent with the primary mode of AV graft failure
linically and similar to the data published in the ovine
odel of PTFE AV grafts. However, the timing of graft
ailure in the present study was improved when one consid-
rs that only 25% of PTFE grafts remained patent by 12
eeks in Kohler’s initial description of the model.16 Clini-
ally, outflow stenosis caused by intimal hyperplasia is a
eading cause of graft failure in autologous and prosthetic
rteriovenous hemodialysis access grafts alike, with average
ime to occlusion for PTFE grafts of 18 months.37 A
imitation of this pilot study, however, is the lack of intra-
nimal control grafts (eg, PTFE or unseeded decellularized
rafts) for comparison. In addition, our use of grafts that
re shorter than the loop grafts used clinically and the
bsence of both renal failure and hemodialysis in our model
ay not entirely replicate the human hemodialysis condi-
ion. Another limitation is the use of TEBV preseeded with
nly EC and not smooth muscle cells. We have recently
eveloped approaches to seed both autologous EC and
collagen deposition at healed needlestick sites. Acute
estick sites by expected findings of adherent thrombus
e (A-C) and healed needlestick (D-F), there are similar
llagen is noted in acute needlestick (C) as compared with
llustrate defects in Verhoeff van Giesen (VVG)-stained
in layers. The scale bar is 200 M.veals
needl
a acut
of co
d E imooth muscle cells in a similar time frame, but future
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September 2012792 Tillman et alstudies are needed to see whether a dual-seeded TEBV can
outperform those with EC alone, particularly as it relates to
venous neointimal hyperplasia and inflammation on a xe-
nogeneic scaffold. Alternative scaffold designs with compli-
ance more similar to the native venous outflow may also be
needed to reduce the impact of compliance mismatch on
venous anastomotic intimal hyperplasia.
In conclusion, this pilot study demonstrates the feasi-
bility of using a bioengineered blood vessel seeded with
autologous progenitor-derived ECs, as an AV graft for
dialysis access. Stable geometry, durable wall structure,
complete cellular healing of needle puncture sites, and
absence of infection were key attributes. Despite these
positive findings, all grafts patent beyond 2 months devel-
oped venous outflow stenosis, and further studies are
needed to determine whether design changes can prevent
this prevalent problem in vascular access.
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